Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations

Statistics in Medicine

Volumn 17, Issue 10, 1998, Pages 1121-1136

  Longini Jr , Ira M ^a   Sagatelian, Karen ^a   Rida, Wasima N ^b   Halloran, M Elizabeth ^a  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; INFECTION SENSITIVITY; POPULATION; VACCINATION;

CLINICAL TRIALS; COMMUNICABLE DISEASE CONTROL; DISEASE SUSCEPTIBILITY; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; VACCINATION;

EID: 2642688638     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19980530)17:10<1121::AID-SIM824>3.0.CO;2-E     Document Type: Article

References (27)

1. Fine, P. E. M. 'Herd immunity: history, theory, practice', Epidemiologic Reviews, 15, 265-302 (1993).
2. Sutter, R. W. and Patriarca, P. A. 'Inactivated and live, attenuated poliovirus vaccines: mucosal immunity', in Kurstak, E. (ed.), Measles and Poliomyelitis, Springer-Verlag, New York, 1993, Chapter 22, pp. 279-294.
3. Takala, A. K., Santosham, M., Almeido-Hill, B. S., Wolff, M., Newcomer, W., Reid, R., Kayhty, H., Esco, E. and Makela, P. H. 'Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children', Pediatric Infectious Diseases Journal, 12, 593-599 (1993).
4. Halloran, M. E. and Struchiner, C. J. 'Modeling transmission dynamics of stage-specific malaria vaccines', Parasitology Today, 8, 77-85 (1992).
5. Halloran, M. E., Struchiner, C. J. and Spielman, A. 'Modeling malaria vaccines II: Population effects of stage-specific malaria vaccines dependent on natural boosting', Mathematical Biosciences, 94, 115-149 (1989).
6. Fast, P. E., Sawyer, L A. and Wescott, S. L. 'Clinical considerations in vaccine trials with special reference to candidate HIV vaccines', in Powell, M. F. and Newman, M. J. (eds), Vaccine Design: The Subunit Adjuvant Approach, Plenum Press, New York, 1995.
7. Jacquez, J. A., Koopman, J. S., Simon, C. P. and Longini, I. M. 'The role of primary infection in the epidemics of HIV infection in gay cohorts', Journal of the Acquired Immune Deficiency Syndrome, 7, 1169-1184 (1994).
8. Koopman, J. S. and Little, R. J. 'Assessing HIV vaccine effects', American Journal of Epidemiology, 142, 1113-1120 (1995).
9. Longini, I. M., Datta, S. and Halloran, M. E. 'Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 13, 440-447 (1996).
10. Datta, S., Halloran, M. E. and Longini, I. M. 'Augmented HIV vaccine trial designs for estimating reduction in infectiousness and protective efficacy', Statistics in Medicine, 17, 185-200 (1998).
11. Rida, W. N. 'Assessing the effect of HIV vaccination', Statistics in Medicine, 15, 2393-2404 (1996).
12. Halloran, M. E. and Struchiner, C. J. 'Causal inference for infectious diseases', Epidemiology, 6, 142-151 (1995).
13. Longini, I. M., Koopman, J. S., Haber, M. and Cotsonis, G. A. 'Statistical inference for infectious diseases: Risk-specified household and community transmission parameters', American Journal of Epidemiology, 128, 845-859 (1988).
14. Longini, I. M. 'The generalized discrete-time epidemic model with immunity: A synthesis', Mathematical Biosciences, 82, 19-41 (1986).
15. Longini, I. M. and Halloran, M. E. 'A frailty mixture model for estimating vaccine efficacy', Applied Statistics, 45, 165-173 (1996).
16. Halloran, M. E., Longini, I. M. and Struchiner, C. J. 'Estimation and interpretation of vaccine efficacy using frailty mixing models', American Journal of Epidemiology, 144, 83-97 (1996).
17. Halloran, M. E., Haber, M. J. and Longini, I. M. 'Interpretation and estimation of vaccine efficacy under heterogeneity', American Journal of Epidemiology, 136, 328-343 (1992).
18. Cox, D. R. and Oakes, D. Analysis of Survival Data, Chapman and Hall, London, 1984.
19. o in models for infectious diseases in heterogeneous populations', Mathematical Biology, 28, 365-382 (1990).
20. Rhodes, P. H., Halloran, M. E. and Longini, I. M. 'Counting process models for differentiating exposure to infection and susceptibility', Journal of the Royal Statistical Society, Series B, 58, 751-762 (1996).
21. Monto, A. S., Davenport, J. A., Napier, J. A. and Francis, T. F. 'Effect of vaccination of a school-age population upon the course of an A2/Hong Kong influenza epidemic', Bulletin of the World Health Organization, 41, 537-542 (1969).
22. Clemens, J. D. Personal communication. 30 October 1996.
23. Grosskurth, H., Mosha, F., Todd, J., Mwijarubi, E., Klokke, A., Senkoro, K., Mayaud, P., Changalucha, J., Nicol, I. A., ka Gina, G., Newell, J., Mugeye, K., Mabey, D. and Hayes, R. 'Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomized controlled trial', Lancet, 346, 530-536 (1995).
24. Halloran, M. E. and Struchiner, C. J. 'Study designs for dependent happenings', Epidemiology, 2, 331-338 (1991).
25. Longini, I. M. and Halloran, M. E. 'AIDS: Modeling epidemic control', Science, 267, 1250-1251 (1995).
26. Haber, M., Longini, I. M. and Halloran, M. E. 'Measures of the effects of vaccination in a randomly mixing population', International Journal of Epidemiology, 20, 300-310 (1991).
27. Luenberger, D. G. Introduction to Dynamic Systems, Wiley, New York, 1979.